Patents by Inventor Jo Alen
Jo Alen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230025025Abstract: The present invention relates to compounds according to general formula (I) which act as inhibitors of NaV1.8 and can be used in the treatment of pain.Type: ApplicationFiled: June 15, 2022Publication date: January 26, 2023Applicant: GRUENENTHAL GMBHInventors: Sebastian KRUEGER, Sebastian PEIL, Clemens DIALER, Marcel MUELBAIER, Markus WAGENER, Ingo KONETZKI, Nikolay SITNIKOV, Jo ALEN, Martin PETTERSSON
-
Publication number: 20220396578Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: July 18, 2022Publication date: December 15, 2022Applicant: GRUENENTHAL GMBHInventors: Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Daniela FRIEBE, Stephanie HENNEN
-
Publication number: 20220372041Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: July 18, 2022Publication date: November 24, 2022Applicant: GRUENENTHAL GMBHInventors: Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Philipp BARBIE, Daniela FRIEBE, Stephanie HENNEN
-
Publication number: 20220127264Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: January 5, 2022Publication date: April 28, 2022Applicant: GRUENENTHAL GMBHInventors: Florian JAKOB, Jo Alen, Sebastian Krueger, Markus Schade, Daniela Friebe, Stephanie Hennen
-
Publication number: 20220106295Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: December 17, 2021Publication date: April 7, 2022Applicant: GRUENENTHAL GMBHInventors: Florian JAKOB, Jo ALEN, Sebastian KRUEGER, Daniela FRIEBE, Stephanie HENNEN
-
Publication number: 20220106294Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: December 17, 2021Publication date: April 7, 2022Applicant: GRUENENTHAL GMBHInventors: Florian JAKOB, Jo ALEN, Sebastian KRUEGER, Philipp BARBIE, Daniela FRIEBE
-
Publication number: 20220089573Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: January 13, 2020Publication date: March 24, 2022Applicant: GRÜNENTHAL GMBHInventors: Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Daniela FRIEBE, Stephanie HENNEN, Philipp BARBIE
-
Publication number: 20210163491Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: February 9, 2021Publication date: June 3, 2021Applicant: Grünenthal GmbHInventors: Florian JAKOB, Jo ALEN, Simon LUCAS, Tobias CRAAN, Ingo KONETZKI, Achim KLESS, Stefan SCHUNK, Paul RATCLIFFE, Sebastian WACHTEN, Simon CRUWYS
-
Publication number: 20210139488Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: January 20, 2021Publication date: May 13, 2021Applicant: GRÜNETHAL GMBHInventors: Florian JAKOB, Jo ALEN, Simon LUCAS, Tobias CRAAN, Ingo KONETZKI, Achim KLESS, Stefan SCHUNK, Paul RATCLIFFE, Sebastian WACHTEN, Simon CRUWYS
-
Patent number: 10981918Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: GrantFiled: July 19, 2019Date of Patent: April 20, 2021Assignee: GRÜNENTHAL GMBHInventors: Florian Jakob, Jo Alen, Simon Lucas, Tobias Craan, Ingo Konetzki, Achim Kless, Stefan Schunk, Paul Ratcliffe, Sebastian Wachten, Simon Cruwys
-
Publication number: 20200223840Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: January 13, 2020Publication date: July 16, 2020Applicant: GRUENENTHAL GMBHInventors: Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Daniela FRIEBE, Stephanie HENNEN, Philipp BARBIE
-
Patent number: 10626106Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: GrantFiled: December 18, 2018Date of Patent: April 21, 2020Assignee: GRUENENTHAL GMBHInventors: Florian Jakob, Jo Alen, Sebastian Krüger, Markus Schade, Daniela Friebe, Stephanie Hennen
-
Publication number: 20200024281Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: July 19, 2019Publication date: January 23, 2020Applicant: Grünenthal GmbHInventors: Florian JAKOB, Jo ALEN, Simon LUCAS, Tobias CRAAN, Ingo KONETZKI, Achim KLESS, Stefan SCHUNK, Paul RATCLIFFE, Sebastian WACHTEN, Simon CRUWYS
-
Publication number: 20190185470Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: December 18, 2018Publication date: June 20, 2019Inventors: Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Markus SCHADE, Daniela FRIEBE, Stephanie HENNEN
-
Publication number: 20190185455Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.Type: ApplicationFiled: December 18, 2018Publication date: June 20, 2019Inventors: Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Markus SCHADE, Daniela FRIEBE, Stephanie HENNEN
-
Patent number: 9174939Abstract: The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.Type: GrantFiled: August 31, 2012Date of Patent: November 3, 2015Assignee: Amakem NVInventors: Jo Alen, Sandro Boland, Arnaud Pierre Jean Bourin, Olivier Defert, Dirk Leysen
-
Patent number: 9079858Abstract: The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and respiratory diseases.Type: GrantFiled: August 31, 2012Date of Patent: July 14, 2015Assignee: Amakem NVInventors: Jo Alen, Sandro Boland, Arnaud Pierre Jean Bourin, Olivier Defert, Dirk Leysen
-
Patent number: 9073905Abstract: The present invention relates to new kinase inhibitors of Formula (I), wherein X is oxygen, —NH—, or a direct bond; Y is —NH— or a direct bond; n is an integer from 0 to 4; m is an integer from 0 to 4; Cy represents a bivalent radical consisting of a satured (poly)cycle, including fused, bi-, spiro or bridged carbocycles and heterocycles; in particular selected from the group consisting of: Formula (II), Ar is selected from the group comprising: Formula (III), R2 is hydrogen or methyl; R8 is hydrogen, methyl, halogen, or alkynyl; R1 is an aryl or heteroaryl more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.Type: GrantFiled: April 27, 2012Date of Patent: July 7, 2015Assignee: Amakem NVInventors: Dirk Leysen, Olivier Defert, Sandro Boland, Jo Alen, Arnaud Pierre Jean Bourin
-
Patent number: 9067889Abstract: The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases, gastrointestinal diseases and respiratory diseases.Type: GrantFiled: August 31, 2012Date of Patent: June 30, 2015Assignee: Amakem NVInventors: Jo Alen, Sandro Boland, Arnaud Pierre Jean Bourin, Olivier Defert, Dirk Leysen
-
Publication number: 20140371268Abstract: The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases, gastrointestinal diseases and respiratory diseases.Type: ApplicationFiled: August 31, 2012Publication date: December 18, 2014Applicant: AMAKEM NVInventors: Jo Alen, Sandro Boland, Arnaud Pierre Jean Bourin, Olivier Defert, Dirk Leysen